A Review of Guselkumab, an IL-23 Inhibitor, for Moderate-to-Severe Plaque Psoriasis.

This article reviews the current status of guselkumab as a therapy for moderate-to-severe plaque psoriasis. PMID: 28329405 [PubMed - in process]
Source: Skin Therapy Letter - Category: Dermatology Authors: Tags: Skin Therapy Lett Source Type: research

Related Links:

In conclusion, immunogenicity data of biosimilars or biosimilar candidates for TNFα or CD20 inh ibitors were collected in trials that varied in design and procedures for ADAb/nAb detection. In general, immunogenicity parameters of biosimilars are similar to those of their reference products.
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research
TUESDAY, Nov. 12, 2019 -- For patients with psoriatic arthritis (PsA), the age of psoriasis onset determines whether arthritis or psoriasis starts first, according to a study presented at the annual meeting of the American College of Rheumatology,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Abstract The advent of biologic agents that target cytokines central to the psoriatic disease cascade have revolutionised the treatment of moderate to severe psoriasis. Methotrexate (MTX) remains the recommended first-line conventional systemic treatment for moderate to severe psoriasis.1 This is due to its well established efficacy, safety profile and low cost1 . Across published data, MTX demonstrates a PASI 75 of approximately 40% at weeks 12-162 , with a median drug survival of 1.8 years.3 The cost of oral MTX is less than 1%, and subcutaneous (SC) MTX less than 10% of that of the cheapest biologic agent in th...
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
AbstractPurpose of ReviewAnkylosing spondyloarthritis (AS) is a chronic inflammatory disease that involves the axial joints and entheses. Extra-spinal manifestations such as anterior uveitis, psoriasis, and colitis also occur frequently. This review on the pathogenesis of AS includes an update on the recent discoveries within the field.Recent FindingsHLA-B*27 is still considered of major importance in the pathogenesis, and it has recently been shown to profoundly affect the gut microbiome and its metabolites and the handling of bacteria during infection. Biochemical and biophysical properties of HLA-B*27 influence its abil...
Source: Current Rheumatology Reports - Category: Rheumatology Source Type: research
Publication date: Available online 9 November 2019Source: International Journal of PharmaceuticsAuthor(s): Sindhu Doppalapudi, Anjali Jain, Wahid Khan, Abraham J. DombAbstractFenoldopam, a highly selective dopamine receptor agonist, is available in clinics as Corlopam™ i.v. for the management of severe hypertension. Recent reports demonstrate its anti-proliferative activity in vitro in a dose dependent manner. However, stability issues of the drug due to its susceptibility to oxidation, pH sensitivity, poor transdermal flux, and the barrier properties of skin present challenges to develop a topical formulation of fen...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Authors: El Jammal T, Gerfaud-Valentin M, Sève P, Jamilloux Y Abstract In the past ten years, the better understanding of the pathophysiological mechanisms underlying inflammatory and autoimmune diseases has led to the emergence of many targeted therapies. Among them, the Janus kinase inhibitors are acting upstream in the inflammatory cascade of several key cytokines in disorders such as rheumatoid arthritis, ulcerative colitis or psoriasis. At the moment, these three diseases represent the only indications validated by the FDA and the EMA of the use of JAK inhibitors apart from hematology. Preclinical data ...
Source: Revue de Medecine Interne - Category: Internal Medicine Tags: Rev Med Interne Source Type: research
Treatment of anti-TNF-related paradoxic palmoplantar psoriasis in Behçet's disease with azathioprine. Clin Exp Rheumatol. 2019 Oct 17; Authors: Karadeniz H, Ataş N, Avanoğlu Güler A, Tufan A PMID: 31694755 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
Conclusions: This review highlights the research in support of common treatments of GPP, including classically used medications and newer monoclonal antibodies, and addresses the continued need for high quality studies regarding treatments for this condition. PMID: 31697211 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
Conclusion: CBT as an adjunct to conventional dermatological treatments may be particularly beneficial for individuals with more severe pretreatment psychopathology in improving psoriasis severity, anxiety, and depression symptoms. CBT appears to be generally effective in improving quality of life. Greater methodological rigour is needed in future research. PMID: 31696748 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
CONCLUSION: IFX Cmin significantly influences PASI 90/100 response rates. IFX Cmin were significantly associated with ATI and BMI. The observed inter-individual variability in IFX Cmin supports the need for IFX drug monitoring. PMID: 31696747 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
More News: Dermatology | Humira | Psoriasis | Skin